Samsung's infliximab biosimilar gets EC approval

Samsung Bioepis Co. Ltd. said the European Commission approved an MAA for Flixabi infliximab ( SB2), a biosimilar of autoimmune drug

Read the full 212 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE